Evidence map›Paper›PMID 24018891›Full record

ReviewInternational journal of molecular sciences2013

Novel strategies for the prevention and treatment of biofilm related infections.

Meng Chen, Qingsong Yu, Hongmin Sun

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 2 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 2 syntheses or guidelines pooled it, 423 citations in OpenAlex.

  1. Molecular imaging of bacterial biofilms-a systematic review.Critical reviews in microbiology · 2024
    Pooled it
  2. Pooled it
  3. Biofilm-Forming Capacity andAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Evaluation of treatment of methicillin-resistantAntimicrobial agents and chemotherapy · 2024
    Article
  17. Article
  18. Antibiofilm Strategies in Neonatal and Pediatric Infections.Antibiotics (Basel, Switzerland) · 2024
    Review
  19. Evaluation of Treatment of Methicillin-ResistantbioRxiv : the preprint server for biology · 2024
    Article
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Meng ChenNanova, Inc. Columbia, MO 65211, USA. sunh@health.missouri.edu.
Qingsong Yu
Hongmin Sun
University of Missouri · USNanova Biomaterials (United States) · US

Funding

Improved long-term biocompatibility of coronary stents by plasma coating processR44HL097485 · NHLBI · NANOVA, INC. · PI CHEN, MENG · 2011 to 2019
$4.6M
NHLBI NIH HHS 1R44HL097485-01A2NHLBI NIH HHS P01HL573461NHLBI NIH HHS R44 HL097485
6 · The paper itself

Abstract

Biofilm formation by human bacterial pathogens on implanted medical devices causes major morbidity and mortality among patients, and leads to billions of dollars in healthcare cost. Biofilm is a complex bacterial community that is highly resistant to antibiotics and human immunity. As a result, novel therapeutic solutions other than the conventional antibiotic therapies are in urgent need. In this review, we will discuss the recent research in discovery of alternative approaches to prevent or treat biofilms. Current anti-biofilm technologies could be divided into two groups. The first group focuses on targeting the biofilm forming process of bacteria based on our understanding of the molecular mechanism of biofilm formation. Small molecules and enzymes have been developed to inhibit or disrupt biofilm formation. Another group of anti-biofilm technologies focuses on modifying the biomaterials used in medical devices to make them resistant to biofilm formation. While these novel anti-biofilm approaches are still in nascent phases of development, efforts devoted to these technologies could eventually lead to anti-biofilm therapies that are superior to the current antibiotic treatment.

Indexed as

Anti-Bacterial AgentsBiocompatible MaterialsBiofilmsHumansAnti-Bacterial AgentsBiocompatible Materials

Identifiers

PMID24018891
PMCPMC3794791
OpenAlexW2084387253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.